Clinical trials: Malignant Solid Tumours
Parent-Child Relations, Cancer
Cancer Parenting Program for the Enhancement of the Quality of Life of Patients With Advanced Cancer and Their Children
This trial examines the usefulness of two educational programs for parents with late-stage cancer who have a 5 - 17 year old child.
- Conditions
- Parent-Child Relations, Cancer, Survivorship, Hematopoietic and Lymphoid System Neoplasm
- Trial name
- EC-PC (NCT05477784)
- Testing
- Group 1: Educational counseling intervention, Group II Active Comparator
- Where
- 2 sites in United States
- Volunteers
- 174 people
- Sponsor
- University of Washington
Advanced Malignant Solid Tumors
Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors
This is a Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Dosing of CM082 tablets in Chinese Patients With Advanced Malignant Solid Tumors
- Trial name
- NCT03792958
- Testing
- CM082
- Where
- China
- Volunteers
- 19 people
- Sponsor
- AnewPharma
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Evaluation of a Couple-Based Physical Activity Intervention
This clinical trial tests how well a couple-based physical activity (PA) intervention, Mates in Motion, works in patients undergoing hematopoietic cell transplantation (HCT) or chimeric antigen receptor T-cell therapy (CART) and…
- Trial name
- NCT06073951
- Testing
- Best Practice, Exercise Counseling, Exercise Intervention
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Neoplasm Malignant
A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
Primary Objective: Part A - Monotherapy: To determine the maximum tolerated dose (MTD) of SAR260301 administered as monotherapy and either on a once or twice daily schedule, to patients with advanced solid tumors or lymphomas.
- Trial name
- NCT01673737
- Testing
- SAR260301, Vemurafenib
- Where
- 4 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- Sanofi
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Outreach Project to Connect Underrepresented Populations to Clinical Trials at Ohio State University, CUSP2CT Project Trial
This clinical trial tests the impact of the The Ohio State University Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) project on clinical trial referrals and enrollment in racial/ethnic minorities.
- Trial name
- NCT06314672
- Testing
- Accrual, Discussion, Educational Activity
- Where
- United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Malignant Solid Tumors, Lymphomas
tTF-NGR Phase I Study
In this phase I clinical trial cancer patients suffering from solid tumors or lymphomas, recurring after and/or refractory against standard treatment are treated intravenously (iv) with increasing doses of tTF-NGR(tTF= truncated…
- Trial name
- NCT02902237
- Testing
- tTF-NGR
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- University Hospital Muenster
Neoplasms, Malignant
Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors
Primary Objective: To determine the maximum administered dose (MAD) and the maximum tolerated dose (MTD) of ombrabulin in combination with best tolerated dose of bevacizumab based on the incidence of related Dose Limiting…
- Trial name
- NCT01193595
- Testing
- Ombrabulin (AVE8062), bevacizumab
- Where
- 4 sites in France, Italy and 1 more
- Volunteers
- 39 people
- Sponsor
- Sanofi
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis
This phase II trial studies how well infliximab and intravenous immunoglobulin therapy work in treating patients with pneumonitis that does not respond to steroid treatment.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Steroid-Refractory Pneumonitis
- Trial name
- NCT04438382
- Testing
- Infliximab, Intravenous Immunoglobulin Therapy, Prednisone
- Where
- 18 sites in United States
- Volunteers
- 1 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Solid Tumors
Kanitinib in Treating Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety , tolerability, pharmacokinetics of Kanitinib and determine the optimal dose in patients with recurrent or metastatic solid tumors.
- Trial name
- NCT02916095
- Testing
- Kanitinib
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Pain; Bone Neoplasms; Neoplasm Metastasis
A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease
This study will assess the efficacy and safety of ibandronate (Bondronat), administered intravenously (IV) or orally (PO), in participants with malignant bone disease and moderate to severe pain.
- Trial name
- NCT02561039
- Testing
- Ibandronate
- Where
- 9 sites in Bulgaria
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Cancer
Effect of Dance-based Multimodal Exercise for Managing CIPN in Cancer Patients
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a significant and distressing symptom experienced by cancer patients with different cancer types.
- Trial name
- NCT07632482
- Testing
- dance-based multimodal exercise, Exercise education
- Volunteers
- 76 people
- Sponsor
- Chinese University of Hong Kong
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain
This phase I trial evaluates the side effects of psilocybin and how well it works under supportive care conditions in cancer survivors living with demoralization and chronic pain.
- Trial name
- NCT05506982
- Testing
- Psilocybin, Psychotherapy, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Emory University
Bladder Cancer, Breast Cancer
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
RATIONALE: Physician-initiated smoking cessation strategies may be effective in getting early-stage cancer patients to quit smoking.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00002520
- Testing
- nicotine, Usual Care
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- Eastern Cooperative Oncology Group
Malignant Neoplasm, Unspecified Adult Solid Tumor, Protocol Specific
Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
Phase I trial to determine the dose of imatinib mesylate that is most effective with the least amount of toxic side effects in treating patients who have advanced cancer and kidney failure.
- Trial name
- NCT00026169
- Testing
- imatinib mesylate, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
COVID-19 Infection, Malignant Solid Neoplasm
Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors
This study uses questionnaires to gain an understanding of how experiences during the COVID-19 pandemic, regardless of COVID-19 status, may have impacted health-related quality of life (HRQOL) and other areas such as…
- Trial name
- NCT04447222
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Survey Administration
- Where
- United States
- Volunteers
- 1,242 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Childhood Malignant Solid Neoplasm, Childhood Malignant Thoracic Neoplasm
An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors
This phase III trial studies how well pafolacianine works for identifying cancerous lesions in children and adolescent patients with primary solid tumors or solid tumors that have spread from where they first started (primary…
- Conditions
- Childhood Malignant Solid Neoplasm, Childhood Malignant Thoracic Neoplasm, Malignant Abdominal Neoplasm, Malignant Neck Neoplasm
- Trial name
- NCT06915727
- Testing
- Biospecimen Collection, Near Infrared Imaging, Pafolacianine Sodium
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
This phase II MATCH treatment trial identifies the effects of crizotinib in patients whose cancer has a genetic change called ALK rearrangement.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439266
- Testing
- Crizotinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Tumors, TGCT
Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
To evaluate the safety and tolerability of HMPL-653 in patients with advanced solid tumors who have failure of standard of care or can not tolerate standard of care or those with TGCT, and to determine the maximum tolerated dose…
- Trial name
- NCT05277454
- Testing
- HMPL-653
- Where
- 5 sites in China
- Volunteers
- 113 people
- Sponsor
- Hutchison Medipharma Limited
Pediatric Malignant Solid Tumor, Febrile Neutropenia (FN)
Phase II Study of QLC2519 in Pediatric Solid Tumor Participants
QLC2519 (Mai Li Sheng®) is a new protein drug created by fusing the N-terminal of highly active modified G-CSF with the C-terminal of HSA.
- Conditions
- Pediatric Malignant Solid Tumor, Febrile Neutropenia (FN), Neutropenia
- Trial name
- NCT07724756
- Testing
- Albipagrastim alf
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.